Benefits of Vascular Normalization Are Dose and Time Dependent—Letter
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Arjaans and colleagues reported that treatment with the anti-VEGF antibody bevacizumab hampers antibody uptake in an ectopic xenograft model of human ovarian cancer in mice (1). They found that bevacizumab decreased vessel number and increased pericyte coverage and concluded that treatment-induced normalization is detrimental for antibody delivery. This conclusion is not supported by their data and is in disagreement with the existing literature (2–4).Vascular normalization after antiangiogenic therapy could explain the seemingly paradoxical synergism between antiangiogenic agents and concurrent systemic anticancer therapies (2). The vascular normalization paradigm was originally described to have four key elements: structural normalization, functional normalization, the transient nature of the effects, and the dose dependence (Fig. 1), with functional normalization being the most important element (2).Arjaans and colleagues used a relatively high dose of bevacizumab and detected structural changes consistent with structural vascular normalization. However, they present no evidence that bevacizumab functionally normalized tumor blood vessels, nor do they mention when antibody treatment was delivered with respect to the vascular normalization time window. These deficiencies notwithstanding, the study raises an important question: Could antiangiogenic therapy impair the delivery of antibodies? The answer is likely yes, as the normalization time window may narrow or even disappear when antiangiogenic agents are dosed to potentiate antivascular effects. Antivascular effects could lead to a transient delay in tumor growth. The remaining vessels may be pericyte-covered, but because these treatments greatly reduce the number of functional vessels, they could potentially hinder the delivery of drugs at that time—a status referred to as “inadequate” rather than “normalized” vasculature (2, 5). This scenario is more consistent with the report by Arjaans and colleagues (1), that is, a predominant antivascular rather than vascular normalizing effect of bevacizumab in their experimental setting. The potential of antiangiogenics to produce both vascular normalizing and antivascular effects is of great clinical relevance for how these drugs should be combined with other therapeutics. Indeed, clinical studies have shown that the addition of high-dose bevacizumab does not improve overall survival when combined with chemotherapeutics in some cancers, such as ovarian or breast cancers. Therefore, it is high time we design better ways for using antiangiogenic therapy in the clinic. Our recent work suggests that anti-VEGFR2 antibody (DC101) treatment can normalize orthotopic tumor vasculature and enhance the delivery of anticancer agents in a dose- and time-dependent manner (Fig. 2; refs. 3, 4). It also shows that these benefits may be lost when using high-dose antiangiogenic therapy due to pronounced antivascular effects. Thus, optimizing combinations of antiangiogenic agents with anticancer treatments will require imaging and/or circulating biomarkers based on an in-depth understanding of the dynamics of the tumor vascular response, in particular the balance between vascular normalizing and antivascular effects.See the Response, p. 7147D.G. Duda is a consultant/advisory board member for Hexal. R.K. Jain is on the board of Xtuit, H&Q Healthcare Investors, and H&Q Life Sciences Investors has grants from MedImmune, and Roche, has ownership interest (including patents) in Enlight, Xtuit, SynDevRx, and is a consultant/advisory board member for Noxxon Pharma, Zyngenia, WebMD, Enlight, and SynDevRx. No potential conflicts of interest were disclosed by the other authors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Self-citationHuang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099 · cited 1×
“Adapted from Huang and colleagues (3).”
Self-citation
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Improving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563
Self-citationStylianopoulos, T., Munn, L. L., & Jain, R. K. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.02.005 · Cited by 563
Self-citationSung, Y.-C., Jin, P.-R., Chu, L.-A., Hsu, F.-F., Wang, M.-R., Chang, C.-C., Chiou, S.-J., Qiu, J. T., Gao, D.-Y., Lin, C.-C., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0570-3 · Cited by 452
El-Sawy, H. S., Al-Abd, A. M., Ahmed, T. A., El-Say, K. M., & Torchilin, V. P. (2018) · ACS Nano · doi:10.1021/acsnano.8b06104 · Cited by 431
Metadata
- Authors
- Huang, Y., Stylianopoulos, T., Duda, D. G., Fukumura, D., & Jain, R. K.
- Venue
- Cancer Research
- Published
- 2013-12-01
- Volume
- 73
- Issue
- 23
- Pages
- 7144-7146
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2083085047
- Cited by
- 110
- References
- 2
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benefits of Vascular Normalization Are Dose and Time Dependent—Letter. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-1989
- The paper
- Huang, Y., Stylianopoulos, T., Duda, D. G., Fukumura, D., & Jain, R. K. (2013). Benefits of Vascular Normalization Are Dose and Time Dependent—Letter. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-1989
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.